John Patrick Shannon Jr. - 29 Jan 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
29 Jan 2022
Net transactions value
-$559,808
Form type
4
Filing time
02 Aug 2024, 17:22:51 UTC
Previous filing
05 Jan 2022
Next filing
01 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +250,000 +12% $0.000000 2,419,612 01 Aug 2024 Direct F1, F2
transaction XERS Common Stock Tax liability $33,110 -15,692 -0.65% $2.11 2,403,920 29 Jan 2022 Direct F3, F4
transaction XERS Common Stock Tax liability $15,819 -7,497 -0.31% $2.11 2,396,423 31 Jan 2022 Direct F3, F5
transaction XERS Common Stock Tax liability $46,294 -41,334 -1.7% $1.12 2,355,089 03 Jan 2023 Direct F3, F6
transaction XERS Common Stock Tax liability $29,502 -23,414 -0.99% $1.26 2,331,675 29 Jan 2023 Direct F3, F7
transaction XERS Common Stock Tax liability $12,251 -9,880 -0.42% $1.24 2,321,795 31 Jan 2023 Direct F3, F8
transaction XERS Common Stock Tax liability $91,468 -40,834 -1.8% $2.24 2,280,961 03 Jan 2024 Direct F3, F9
transaction XERS Common Stock Tax liability $58,919 -22,150 -0.97% $2.66 2,258,811 29 Jan 2024 Direct F3, F10
transaction XERS Common Stock Tax liability $272,445 -110,750 -4.9% $2.46 2,148,061 31 Jan 2024 Direct F3, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +300,000 $0.000000 300,000 01 Aug 2024 Common Stock 300,000 $2.43 Direct F12, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 These shares include 11,037 shares that were purchased on June 30, 2024, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
F3 This transaction is being reported late due to administrative oversight.
F4 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
F5 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
F6 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
F7 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
F8 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
F9 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
F10 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
F11 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.
F12 The award will vest in full on the two-year anniversary of the grant date.
F13 Upon exercise, the Stock Appreciation Right will be settled in cash.

Remarks:

Chief Executive Officer and Director